Tumors and inflammation have a close association, which is a popular topic in cancer research. Inflammation can hasten the onset and progression of cancer by boosting blood vessel expansion, cancer cell proliferation, and tumor invasiveness and adversely influencing immune response and altering the efficiency of some anti-tumor medications.
Moreover, it has been proven that the tumor microenvironment contains a considerable number of inflammatory substances and inflammatory cells and that tumor-promoting immunity and anti-tumor immunity coexist. Inflammatory cells enhance the incidence and growth of cancers.
Cancer prediction and prevention necessitate selecting the most appropriate treatments for the cause. An individualized patient profile is a reasonable approach since it can comprehend specific details such as thorough fundamental information, family background, and medical history. Chronic inflammation has been linked to the onset and progression of cancer.
Finding clinical diagnostic indicators for early cancer is critical. Inflammation is connected to all malignancies, particularly GC, liver cancer, and lung cancer. I believe that it is critical to investigate biomarkers for cancer prevention and prognosis to determine how chronic inflammation generates cancer, how cancer evolves, and if chronic inflammation is created independently or is triggered by acute inflammation.
Notably, multiple different triggers cause inflammation in malignancies. Some of them, such as carcinogenic microbes, environmental contaminants, such as smoke, low-grade inflammation associated with obesity, and commensal microorganisms associated with epithelial-barrier deterioration, may be critical targets for cancer prevention.
Thus, in order to reduce tumor-initiating inflammation, it is vital to remove or neutralize the original stimulus. Cancer prevention can be accomplished by immunizations, nutritional changes, a better knowledge of antibiotic use, and improved environmental protection.